iBio (NASDAQ:IBIO) Releases Earnings Results, Beats Estimates By $0.02 EPS

iBio (NASDAQ:IBIO) posted its earnings results on Tuesday. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02, FiscalAI reports. The firm had revenue of $1.07 million for the quarter, compared to the consensus estimate of $0.03 million.

Here are the key takeaways from iBio’s conference call:

• iBio has become a clinical-stage company: its IBIO-600 myostatin/GDF11 antibody has completed single-ascending-dose testing, with the company reporting no concerning safety findings so far. Unblinded safety, half-life and possible body-composition data are expected in the first quarter of next year.
• The company highlighted non-human-primate results for its Activin E antibody, IBIO-610, saying it shifted GLP-1-associated weight loss toward fat rather than muscle; it cautioned that the study is not complete. iBio is targeting an Australian clinical-trial filing by year-end and first-in-human data in the first half of next year, with the initial study focused mainly on safety and pharmacokinetics.
• IBIO-800, a myostatin/Activin A bispecific being developed initially for PH-HFpEF, is in CMC and toxicology work, with animal efficacy results expected by the end of the second quarter next year. The company is still evaluating potential bleeding and blood-cell-production risks, so both the safety profile and clinical prospects remain uncertain.
• The amylin program remains in candidate-selection work: iBio is comparing receptor and signaling profiles and expects to choose a development candidate around mid-next year. The company said CMC and toxicology would then take another 9–12 months before the program could enter the clinic.
• Management said current cash is expected to fund operations into the second quarter of 2028 and support several planned data readouts, but also expects the company will need to raise capital sometime in the next year. That could create financing or dilution risk if partnering or other non-dilutive funding does not materialize.

iBio Stock Down 3.3%

NASDAQ:IBIO traded down $0.03 during mid-day trading on Thursday, hitting $0.80. 132,520 shares of the stock traded hands, compared to its average volume of 1,065,313. The stock has a market capitalization of $51.26 million, a price-to-earnings ratio of -2.85 and a beta of 1.47. iBio has a 52 week low of $0.69 and a 52 week high of $3.82. The firm’s 50 day moving average is $1.00 and its two-hundred day moving average is $1.64.

Analysts Set New Price Targets

IBIO has been the subject of several research reports. Wall Street Zen lowered shares of iBio from a “hold” rating to a “sell” rating in a research report on Sunday, September 13th. HC Wainwright initiated coverage on shares of iBio in a report on Thursday, September 17th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of iBio in a research report on Monday, September 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $6.00.

About iBio

iBio, Inc. (NASDAQ: IBIO) is a biotechnology company focused on discovering and developing next-generation antibody therapeutics. The company uses artificial intelligence, machine learning and computational biology to identify and optimize antibody candidates for potential use in cancer and other serious diseases. iBio’s discovery capabilities are built around proprietary antibody-design and profiling technologies, including platforms intended to improve the speed and quality of therapeutic antibody development.